4.7 Article

Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock Findings From the NCDR

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.11.048

关键词

cause of death; follow-up studies; heart failure; outcomes assessment; patient readmission; prognosis

资金

  1. Society of Cardiovascular Patient Care
  2. American College of Emergency Physicians
  3. American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR)
  4. Abbott Diagnostics
  5. St. Jude Medical
  6. Boston Scientific
  7. Bristol-Myers Squibb
  8. Daiichi-Sankyo
  9. Eli Lilly
  10. Gilead Sciences
  11. GlaxoSmithKline
  12. Regeneron Pharmaceuticals
  13. AstraZeneca
  14. Premier, Inc.
  15. Johnson Johnson
  16. Bayer Healthcare
  17. Gilead
  18. Eisai
  19. Merck
  20. Arena
  21. BioagenIdec
  22. Boehringer Ingelheim
  23. Boston Clinical Research Institute
  24. Covance
  25. Elsevier Practice Update Cardiology
  26. Forest Pharmaceuticals
  27. GE Healthcare
  28. Lexicon
  29. University of Calgary
  30. Hoffman-La Roche
  31. Medtronic Foundation
  32. Merck Co.
  33. Pfizer
  34. Sanofi
  35. Takeda
  36. The Medicines Company
  37. Janssen Pharmaceuticals
  38. Bayer
  39. Armethon

向作者/读者索取更多资源

BACKGROUND Many patients with acute myocardial infarction (AMI) and cardiogenic shock survive hospitalization; little is known about their subsequent prognosis. OBJECTIVES This study sought to evaluate the associations between cardiogenic shock and post-discharge mortality and all-cause hospitalization among hospital survivors. METHODS We included patients >= 65 years of age with AMI from the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines) who survived hospitalization and linked these patients with Medicare claims data. We used proportional hazards models to test the association between cardiogenic shock and outcomes, adjusting for patient and hospital characteristics. Hazard ratios (HRs) are reported for early (1 to 60 days) and late (61 to 365 days) post-discharge time periods. RESULTS Among 112,668 AMI survivors, 5% had cardiogenic shock during hospitalization. The rate of death was significantly higher among patients with cardiogenic shock at 60 days (9.6% vs. 5.5%) and 1 year (22.4% vs. 16.7%). After accounting for baseline characteristics, the risk of death remained higher for cardiogenic shock patients in the first 60 days after discharge (adjusted HR: 1.62; 95% confidence interval [CI]: 1.46 to 1.80), but was similar to nonshock patients thereafter (adjusted HR: 1.08 for days 61 to 365; 95% CI: 1.00 to 1.18). The rate of all-cause hospitalization or death was significantly higher among shock patients at 60 days (33.9% vs. 24.9%) and 1 year (59.1% vs. 52.3%). After adjustment, the risk of this outcome was also clustered in the first 60 days (adjusted HR: 1.28; 95% CI: 1.21 to 1.35) and was similar thereafter (adjusted HR: 0.95 for days 61 to 365; 95% CI: 0.89 to 1.01). CONCLUSIONS Hospital survivors of AMI who had cardiogenic shock have a higher risk of death and/ or hospitalization during the first year after discharge. The risk is time-dependent and is clustered in the early post-discharge period, after which the prognosis is similar in patients with and without cardiogenic shock. (C) 2016 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据